An Exploratory Study of the Biologic Effects of Nivolumab and Ipilumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced Melanaoma (Unresectable or Metastatic)

Trial Profile

An Exploratory Study of the Biologic Effects of Nivolumab and Ipilumab Monotherapy and Nivolumab in Combination with Ipilimumab Treatment in Subjects with Advanced Melanaoma (Unresectable or Metastatic)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Biomarker; Pharmacodynamics
  • Acronyms PD-1
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results of serum metabolomics in nivolumab-treated patients from this and other trial (CA209-009 study) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Apr 2017 Results assessing genomic changes in tumors in patients receiving nivolumab who were ipilimumab naive or who progressed on ipilimumab (n=85), presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top